Janssen

Janssen UK (Johnson & Johnson Innovative Medicine) is the pharmaceutical division of Johnson & Johnson, developing transformative medicines in oncology, immunology, neuroscience, cardiovascular disease, and infectious diseases. Key products include Darzalex (daratumumab) for multiple myeloma, Stelara (ustekinumab) for psoriasis, Crohn’s disease, and ulcerative colitis, Tremfya (guselkumab) for psoriasis, Invega for schizophrenia, and Symtuza for HIV treatment.